Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab Plus Ramucirumab in Recurrent/Advanced NSCLC
NCT03527108Phase 2Active, not recruiting
- Sponsor
- Fox Chase Cancer Center
- Start
- Oct 2020
- Primary completion
- Dec 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ramucirumab in non-small cell lung cancer (NSCLC), sponsored by Fox Chase Cancer Center. Started Oct 2020; status: active, not recruiting.
02
Drugs
nivolumabramucirumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03527108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03527108.